Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
ArriVent's oral lung cancer drug firmonertinib failed to meaningfully delay disease progression in a late-stage trial, sending shares tumbling nearly 60%. The drug, targeting a rare EGFR exon 20 insertion mutation in non-small cell lung cancer (NSCLC), extended median progression-free survival by just 1.5 months over chemotherapy — a gap the company's own CEO called not "meaningful." The company is now reassessing its development strategy.
ArriVent BioPharma's oral therapy firmonertinib has hit a major wall. In a late-stage trial, the drug failed to meaningfully delay disease progression in previously untreated patients with advanced NSCLC harboring an EGFR exon 20 insertion mutation — a rare genetic alteration that drives cancer growth in roughly 0.5%–1% of NSCLC cases. NSCLC itself accounts for about 85% of all lung cancers, making this mutation a small but significant patient population with limited treatment options.
The disappointing results sent ArriVent's shares plunging nearly 60%. Analysts noted the trial's shortfall was largely driven by an overperforming control arm — chemotherapy delivered 9.5 months of progression-free survival versus the expected 7.5–8 months — rather than firmonertinib underperforming. The company says no new safety signals were identified and is evaluating the full dataset to determine next steps.
By the Numbers:
Why it matters: While the exon 20 program faces a serious setback, ArriVent still has a separate late-stage trial running for NSCLC patients with uncommon EGFR PACC mutations, which analysts say retains clinical promise. Patients with rare EGFR mutations continue to have few effective options, underscoring the urgent need for better-targeted therapies.
